MedWatch

Demant reports record operating result

The excitement surrounding Demant’s full-year 2021 report was punctured slightly by the accidental release of key figures on Sunday evening – but the report released on Tuesday morning still contains some interesting growth predictions. (Updated)

Photo: Demant / PR

Hearing aid firm Demant released its full-year financial report for 2021 on Tuesday morning, but the most important figures did not come as a surprise.

In 2021, Demant generated organic growth of 27 percent and an EBIT operating result of DKK 3.4bn (USD 520m). Both figures were accidentally published on the company’s website on Sunday evening, and confirmed by a stock exchange notification on Monday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs